var data={"title":"Amoxicillin and clavulanate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amoxicillin and clavulanate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5632?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amoxicillin-and-clavulanate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amoxicillin and clavulanate: Patient drug information&quot;</a> and <a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Amoxicillin and clavulanate: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134614\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Augmentin;</li>\n      <li>Augmentin ES-600;</li>\n      <li>Augmentin XR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134615\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Amoxi-Clav;</li>\n      <li>Apo-Amoxi-Clav;</li>\n      <li>Clavulin;</li>\n      <li>Novo-Clavamoxin;</li>\n      <li>ratio-Aclavulanate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134635\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Penicillin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134618\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose is based on the amoxicillin component. Dose and frequency are product specific; not all products are interchangeable. Using a product with the incorrect amoxicillin:clavulanate ratio could result in subtherapeutic clavulanic acid concentrations or severe diarrhea. For adults who have difficulty swallowing the tablets, the 125 mg/5 mL or 250 mg/5 mL suspension may be given in place of the 500 mg/125 mg tablet; the 200 mg/5 mL or 400 mg/5 mL suspension may be given in place of the 875 mg/125 mg tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Susceptible infections:</b> Oral: Immediate release: 250 mg every 8 hours or 500 mg every 8 to 12 hours <b>or</b> 875 mg every 12 hours <b>or</b> Extended release: 2,000 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bite wounds (animal/human) (off-label use):</b> Oral: Immediate release: 875 mg every 12 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic obstructive pulmonary disease (COPD) (off-label use):</b> Oral: Immediate release: 500 mg every 8 hours (Llor 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cystitis, acute uncomplicated:</b> Oral: Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling:</i> 500 mg every 12 hours or 250 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing:</i> 500 mg every 12 hours for 7 days (Colgan 2011; IDSA [Gupta 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Impetigo (off-label use):</b> Oral: Immediate release: 875 mg every 12 hours for 7 days, depending on response (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Febrile neutropenia, empiric therapy in low-risk cancer patients (off-label use): </b>Oral: Immediate release: 500 mg every 8 hours until resolution of neutropenia; use in combination with oral ciprofloxacin (Freifeld 1999; Pherwani 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Group A streptococci chronic carrier, treatment (off-label use):</b> Oral: Immediate release: Amoxicillin 40 mg/kg/day divided every 8 hours (maximum: Amoxicillin 2,000 mg/day) for 10 days (IDSA [Shulman 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired (CAP):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer&rsquo;s labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: 875 mg every 12 hours <b>or</b> 500 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: 2,000 mg every 12 hours for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Outpatient empiric therapy: Extended release: 2,000 mg every 12 hours for a minimum of 5 days (patients should be afebrile for &ge;48 hours and clinically stable before discontinuation of therapy); use in combination with a macrolide (preferred) or doxycycline (Mandell 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meliodosis, treatment (eradication phase) and postexposure prophylaxis (off-label use) (HHS [Lipsitz 2012]): </b>Oral: Immediate release: <b>Note:</b> Duration for eradication phase treatment is &ge;12 weeks; duration for postexposure prophylaxis is 21 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;60 kg: 1,500 mg (three 500 mg tablets) every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;60 kg: 1,000 mg (two 500 mg tablets) every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prosthetic joint infection, chronic antimicrobial suppression, oxacillin-susceptible <i>Staphylococci </i>(alternative to cephalexin or cefadroxil) (off-label use):</b> Oral: Immediate release: 500 mg 3 times daily (IDSA [Osmon 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Respiratory tract infections, lower:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: 875 mg every 12 hours <b>or</b> 500 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sinusitis, acute bacterial:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: 500 mg every 8 hours or amoxicillin 875 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: Amoxicillin 2,000 mg every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing:</i> IDSA recommendations:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Standard dose: Immediate release: 500 mg every 8 hours or 875 mg every 12 hours for 5 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High dose: Extended release: 2,000 mg every 12 hours for 10 days. <b>Note:</b> Recommended for patients with any of the following: If initial therapy fails (as second-line therapy), in areas with high endemic rates of penicillin-nonsusceptible <i>S. pneumoniae</i>, those with severe infections, age &gt;65 years, recent hospitalization, antibiotic use within the past month, or who are immunocompromised (AAO-HNS [Rosenfeld 2015]; IDSA [Chow 2012]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134628\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Amoxicillin and clavulanate: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose is based on the amoxicillin component. Dose and frequency are product specific; not all products are interchangeable. Using a product with the incorrect amoxicillin:clavulanate ratio could result in subtherapeutic clavulanic acid concentrations or severe diarrhea.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &lt;3 months: Oral: Amoxicillin 30 mg/kg/day divided every 12 hours using the 125 mg per 5 mL suspension <b>only</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;3 months, Children, and Adolescents &lt;40 kg: Oral: Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infections: Amoxicillin 25 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or 200 mg or 400 mg chewable tablets) <b>or</b> amoxicillin 20 mg/kg/day in divided doses 3 times daily (using the 125 mg per 5 mL or 250 mg per 5 mL suspension) (maximum single dose: 500 mg amoxicillin)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infections: Amoxicillin 45 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or 200 mg or 400 mg <b>chewable</b> tablets) (maximum single dose: Amoxicillin 875 mg) <b>or</b> amoxicillin 40 mg/kg/day in divided doses 3 times daily (using the 125 mg per 5 mL or 250 mg per 5 mL suspension) (maximum single dose: Amoxicillin 500 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents &ge;40 kg: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infections: Immediate release: Amoxicillin 500 mg every 12 hours (using the 500 mg tablet; if difficulty swallowing the 125 mg per 5 mL or 250 mg per 5 mL suspension may be used) <b>or</b> 250 mg amoxicillin every 8 hours (using the 250 mg tablet)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infections:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immediate release: Amoxicillin 875 mg every 12 hours (using the 875 mg tablet; if difficulty swallowing, the 200 mg per 5 mL or 400 mg per 5 mL suspension may be used) <b>or</b> amoxicillin 500 mg every 8 hours (using the 500 mg tablet; if difficulty swallowing, the 125 mg per 5 mL or 250 mg per 5 mL suspension may be used).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Extended release: Amoxicillin 2,000 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Group A streptococci chronic carrier, treatment (off-label use):</b> Infants &ge;3 months, Children, and Adolescents: Oral: Immediate release: Amoxicillin 40 mg/kg/day divided every 8 hours for 10 days (using the 125 mg per 5 mL or 250 mg per 5 mL suspension) (IDSA [Shulman 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Impetigo (off-label use):</b> Infants &ge;3 months, Children, and Adolescents: Oral: Immediate release: Amoxicillin 25 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL oral suspension or the 200 mg or 400 mg <b>chewable</b> tablets) (maximum single dose: 875 mg amoxicillin) (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Otitis media, acute: </b> Infants &ge;6 months and Children: Oral: Immediate release: Amoxicillin 90 mg/kg/day divided every 12 hours (using the 600 mg per 5 mL suspension <b>only</b>). <b>Note:</b> Use for severe illness, those who have received amoxicillin in the past 30 days, who have treatment failure at 48 to 72 hours on first-line therapy, and when coverage for beta-lactamase positive <i>H. influenzae</i> and <i>M. catarrhalis</i> is needed. Variable duration of therapy; the manufacturer&rsquo;s labeling suggests 10-day course in all patients; however, new data suggest a shorter-course in some cases: If &lt;2 years of age or severe symptoms (any age): 10-day course; if 2 to 5 years of age with mild to moderate symptoms: 7-day course; if &ge;6 years of age with mild to moderate symptoms: 5- to 7-day course (AAP [Lieberthal 2013]). <b>Note:</b> Per the manufacturer, the 600 mg/5 mL formulation should only be used for patients weighing &lt;40 kg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, community-acquired (CAP) and respiratory tract infections, lower:</b> Infants &ge;3 months, Children, and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer's labeling: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients weighing &lt;40 kg: Immediate release: Amoxicillin 45 mg/kg/day in divided doses twice daily (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or the 200 mg or 400 mg chewable tablets) (maximum single dose: Amoxicillin 875 mg) <b>or</b> amoxicillin 40 mg/kg/day in divided doses 3 times daily (using the 125 mg per 5 mL or 250 mg per 5 mL suspension) (maximum single dose: Amoxicillin 500 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients weighing &ge;40 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Immediate release: Amoxicillin 875 mg every 12 hours using the 875 mg tablet or if difficulty swallowing, the 200 mg/5 mL or the 400 mg/5 mL oral suspension may be used or 500 mg amoxicillin every 8 hours using the 500 mg tablet or if difficulty swallowing, the 125 mg/5 mL or 250 mg/5 mL oral suspension may be used</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Extended release: 2,000 mg amoxicillin every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate dosing</i> (off-label dosing): Beta-lactamase positive <i>H. influenzae</i> strains (IDSA/PIDS [Bradley 2011]): Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Standard dose: Amoxicillin 45 mg/kg/day in divided doses 3 times daily (using the 125 mg per 5 mL or 250 mg per 5 mL suspension) (maximum single dose: Amoxicillin 500 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High dose: Amoxicillin 90 mg/kg/day in divided doses 2 times daily (using the 600 mg per 5 mL suspension). <b>Note:</b> A wider dosing range of 80 to 100 mg/kg/day divided every 8 hours has also been used (Bradley 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sinusitis, acute bacterial: </b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>IDSA recommendations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;3 months, Children, and Adolescents &lt;40 kg: Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Standard dose: Amoxicillin 45 mg/kg/day divided every 12 hours for 10 to 14 days (using the 200 mg per 5 mL or 400 mg per 5 mL suspension or 200 mg or 400 mg chewable tablets <b>only</b>) (IDSA [Chow 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">High dose (off-label dose): Amoxicillin 90 mg/kg/day divided every 12 hours for 10 to 14 days (using the 600 mg per 5 mL suspension <b>only</b>). <b>Note:</b> Use recommended in the following: If initial therapy fails (as second-line therapy), in areas with high endemic rates of penicillin-nonsusceptible <i>S. pneumoniae</i>, those with severe infections, daycare attendance, age &lt;2 years, recent hospitalization, antibiotic use within the past month, or who are immunocompromised (IDSA [Chow 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents &ge;40 kg: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>AAP recommendations:</i> Children and Adolescents: Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High dose (off-label dose): Amoxicillin 80 to 90 mg/kg/day divided every 12 hours (using the 600 mg per 5 mL oral suspension <b>only</b>); treatment duration variable: 10 to 28 days, some have suggested discontinuation of therapy 7 days after resolution of signs and symptoms of infection. <b>Note:</b> Recommended for patients with any of the following: moderate to severe infection, age &lt;2 years, childcare attendance, or recent antibiotic treatment. (Wald 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infections:</b> Infants and Children 2 to 24 months: Oral: Immediate release: Amoxicillin 20 to 40 mg/kg/day in divided doses 3 times daily (using the 125 mg per 5 mL or 250 mg per 5 mL suspension); (maximum single dose: Amoxicillin 500 mg) (AAP 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134619\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134620\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adults:<b> Note:</b> Renally adjusted dose recommendations are based on the amoxicillin 250 mg/clavulanate 125 mg and amoxicillin 500 mg/clavulanate 125 mg tablets.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 10 to 30 mL/minute: 250 to 500 mg every 12 hours; do not use 875 mg tablet or extended-release tablets</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;10 mL/minute: 250 to 500 mg every 24 hours; do not use 875 mg tablet or extended-release tablets</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">End-stage renal disease (ESRD) on hemodialysis: 250 to 500 mg amoxicillin every 24 hours; administer dose both during and after dialysis. Do not use 875 mg tablet or extended-release tablets.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended (Aronoff 2007): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mild to moderate infection: Dosing based on amoxicillin 25 to 50 mg/kg/day divided every 8 hours: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">GFR &ge;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Amoxicillin 8 to 20 mg/kg/dose every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Amoxicillin 8 to 20 mg/kg/dose every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">End-stage renal disease (ESRD): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Hemodialysis: Amoxicillin 8 to 20 mg/kg/dose every 24 hours; give after dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Peritoneal dialysis: Amoxicillin 8 to 20 mg/kg/dose every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Severe infection (high dose): Dosing based on amoxicillin 80 to 90 mg/kg/day divided every 12 hours: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &ge;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl 10 to 29 mL/minute/1.73 m<sup>2</sup>: Amoxicillin 20 mg/kg/dose every 12 hours; do not use the 875 mg tablet </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>: Amoxicillin 20 mg/kg/dose every 24 hours; do not use the 875 mg tablet </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">End-stage renal disease (ESRD): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Hemodialysis: Amoxicillin 20 mg/kg/dose every 24 hours; give after dialysis; do not use the 875 mg tablet </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Peritoneal dialysis: Amoxicillin 20 mg/kg/dose every 24 hours; do not use the 875 mg tablet </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673178\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution. Use contraindicated in patients with a history of amoxicillin and clavulanate-associated hepatic dysfunction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134591\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder for suspension, oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Augmentin:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">125: Amoxicillin 125 mg and clavulanate potassium 31.25 mg per 5 mL (75 mL, 100 mL, 150 mL) [contains potassium 0.16 mEq/5 mL; banana flavor] </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">200: Amoxicillin 200 mg and clavulanate potassium 28.5 mg per 5 mL (50 mL, 75 mL, 100 mL) [contains phenylalanine 7 mg/5 mL and potassium 0.14 mEq/5 mL; orange flavor] [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">250: Amoxicillin 250 mg and clavulanate potassium 62.5 mg per 5 mL (75 mL, 100 mL, 150 mL) [contains potassium 0.32 mEq/5 mL; orange flavor] </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">400: Amoxicillin 400 mg and clavulanate potassium 57 mg per 5 mL (50 mL, 75 mL, 100 mL) [contains phenylalanine 7 mg/5 mL and potassium 0.29 mEq/5 mL; orange flavor] [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Augmentin ES-600:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">600: Amoxicillin 600 mg and clavulanate potassium 42.9 mg per 5 mL (75 mL, 125 mL, 200 mL) [contains phenylalanine 7 mg/5 mL, potassium 0.23 mEq/5 mL; strawberry cream flavor]</p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Generic: 200: Amoxicillin 200 mg and clavulanate potassium 28.5 mg per 5 mL (50 mL, 75 mL, 100 mL); 250: Amoxicillin 250 mg and clavulanate potassium 62.5 mg per 5 mL (75 mL, 100 mL, 150 mL); 400: Amoxicillin 400 mg and clavulanate potassium 57 mg per 5 mL (50 mL, 75 mL, 100 mL); 600: Amoxicillin 600 mg and clavulanate potassium 42.9 mg per 5 mL (75 mL, 125 mL, 200 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Tablet, oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Augmentin:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">250: Amoxicillin 250 mg and clavulanate potassium 125 mg [contains potassium 0.63 mEq/tablet] [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">500: Amoxicillin 500 mg and clavulanate potassium 125 mg [contains potassium 0.63 mEq/tablet]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">875: Amoxicillin 875 mg and clavulanate potassium 125 mg [contains potassium 0.63 mEq/tablet]</p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Generic: 250: Amoxicillin 250 mg and clavulanate potassium 125 mg; 500: Amoxicillin 500 mg and clavulanate potassium 125 mg; 875: Amoxicillin 875 mg and clavulanate potassium 125 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Tablet, chewable, oral: </p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Generic: 200: Amoxicillin 200 mg and clavulanate potassium 28.5 mg [contains phenylalanine]; 400: Amoxicillin 400 mg and clavulanate potassium 57 mg [contains phenylalanine]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, extended release, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Augmentin XR: 1000: Amoxicillin 1000 mg and clavulanate acid 62.5 mg [contains potassium 12.6 mg (0.32 mEq) and sodium 29.3 mg (1.27 mEq) per tablet; packaged in either a 7-day or 10-day package]</p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Generic:  1000: Amoxicillin 1000 mg and clavulanate acid 62.5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134575\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21964564\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for suspension, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clavulin:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">125: Amoxicillin 125 mg and clavulanate potassium 31.25 mg per 5 mL (100 mL) [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">200: Amoxicillin 200 mg and clavulanate potassium 28.5 mg per 5 mL (70 mL) [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">250: Amoxicillin 250 mg and clavulanate potassium 62.5 mg per 5 mL (100 mL) [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">400: Amoxicillin 400 mg and clavulanate potassium 57 mg per 5 mL (70 mL) [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clavulin:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">500: Amoxicillin 500 mg and clavulanate potassium 125 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">875: Amoxicillin 875 mg and clavulanate potassium 125 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134595\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer around-the-clock to promote less variation in peak and trough serum levels. Administer with food to increase absorption and decrease stomach upset; shake suspension well before use. Extended release tablets should be administered with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134594\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired:</b> Extended-release tablets only: Treatment of patients with  community-acquired pneumonia (CAP) caused by confirmed or suspected beta-lactamase-producing pathogens (ie, <i>Haemophilus influenzae</i>, <i>Moraxella catarrhalis</i>, <i>Haemophilus parainfluenzae</i>, <i>Klebsiella pneumoniae</i>, methicillin-susceptible <i>Staphylococcus aureus</i>) and <i>Streptococcus pneumoniae</i> with reduced susceptibility to penicillin (penicillin minimum inhibitory concentration [MIC] = 2 mcg/mL). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Augmentin XR is not indicated for the treatment of infections caused by <i>S. pneumoniae</i> with penicillin MIC of 4 mcg/mL or greater (limited data).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Otitis media, acute: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release tablets, chewable tablets, oral suspension (400/57 mg per 5 mL, 250/62.5 mg per 5 mL, 200/28.5 mg per 5 mL, and 125/31.25 mg per 5 mL only): Treatment of otitis media caused by beta-lactamase-producing strains of <i>H. influenzae</i> and <i>M. catarrhalis</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral suspension (600/42.9 mg per 5 mL concentration): Treatment of acute otitis media, recurrent or persistent, caused by <i>S. pneumoniae</i> (penicillin MIC = 2 mcg/mL or less), <i>H. influenzae</i> (including beta-lactamase-producing strains), and <i>M. catarrhalis</i> (including beta-lactamase-producing strains) in pediatric patients with a history of antibiotic exposure for acute otitis media in the preceding 3 months and who are either 2 years or younger or attend day care; treatment of otitis media caused by beta-lactamase-producing strains of <i>H. influenzae</i> and <i>M. catarrhalis</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Respiratory tract infections, lower:</b> Immediate-release tablets, chewable tablets, oral suspension (400/57 mg per 5 mL, 250/62.5 mg per 5 mL, 200/28.5 mg per 5 mL, and 125/31.25 mg per 5 mL only): Treatment of lower respiratory tract infection caused by beta-lactamase-producing strains of <i>H. influenzae</i> and <i>M. catarrhalis</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sinusitis, acute bacterial:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release tablets: Treatment of patients with acute bacterial sinusitis caused by confirmed or suspected beta-lactamase-producing pathogens (ie, <i>H. influenzae</i>, <i>M. catarrhalis</i>, <i>H. parainfluenzae</i>, <i>K. pneumoniae</i>, methicillin-susceptible <i>S. aureus</i>) and <i>S. pneumoniae</i> with reduced susceptibility to penicillin (penicillin MIC = 2 mcg/mL). </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Limitations of use: Augmentin XR is not indicated for the treatment of infections caused by <i>S. pneumoniae</i> with penicillin MIC of 4 mcg/mL or greater (limited data). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release tablets, chewable tablets, oral suspension (400/57 mg per 5 mL, 250/62.5 mg per 5 mL, 200/28.5 mg per 5 mL, and 125/31.25 mg per 5 mL only): Treatment of sinusitis caused by beta-lactamase-producing strains of <i>H. influenzae</i> and <i>M. catarrhalis</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections:</b> Immediate-release tablets, chewable tablets, oral suspension (400/57 mg per 5 mL, 250/62.5 mg per 5 mL, 200/28.5 mg per 5 mL, and 125/31.25 mg per 5 mL only): Treatment of skin and skin structure infections caused by beta-lactamase-producing strains of <i>S. aureus</i>, <i>Escherichia coli</i>, and <i>Klebsiella</i> spp. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infections:</b> Immediate-release tablets, chewable tablets, oral suspension (400/57 mg per 5 mL, 250/62.5 mg per 5 mL, 200/28.5 mg per 5 mL, and 125/31.25 mg per 5 mL only): Treatment of urinary tract infections caused by beta-lactamase-producing strains of <i>E. coli</i>, <i>Klebsiella</i> spp, and <i>Enterobacter</i> spp.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475042\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bite wounds (animal/human); Febrile neutropenia, empiric therapy (oral) in low-risk cancer patients; Group A streptococci chronic carrier, treatment; Impetigo; Melioidosis, treatment (eradication phase) and postexposure prophylaxis; Prosthetic joint infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134644\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Augmentin may be confused with amoxicillin, Azulfidine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134582\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: Gastrointestinal: Diarrhea (3% to 34%; incidence varies upon dose and regimen used) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Diaper rash, skin rash, urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Abdominal distress, loose stools, nausea, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Candidiasis, vaginal mycosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Cholestatic jaundice, flatulence, headache, hepatic insufficiency, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014), increased liver enzymes, increased serum alkaline phosphatase, prolonged prothrombin time, thrombocythemia, vasculitis (hypersensitivity)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Additional adverse reactions seen with <b>ampicillin-class antibiotics:</b> Acute generalized exanthematous pustulosis, agitation, agranulocytosis, anaphylaxis, anemia, angioedema, anxiety, behavioral changes, confusion, convulsions, crystalluria, dental discoloration, dizziness, dyspepsia, enterocolitis, eosinophilia, erythema multiforme, exfoliative dermatitis, gastritis, glossitis, hematuria, hemolytic anemia, hemorrhagic colitis, hyperactivity, immune thrombocytopenia, increased serum bilirubin, increased serum transaminases, insomnia, interstitial nephritis, leukopenia, melanoglossia, mucocutaneous candidiasis, pruritus, pseudomembranous colitis, serum sickness-like reaction, Stevens-Johnson syndrome, stomatitis, thrombocytopenia, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134598\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to amoxicillin, clavulanic acid, other beta-lactam antibacterial drugs (eg, penicillins, cephalosporins), or any component of the formulation; history of cholestatic jaundice or hepatic dysfunction with amoxicillin/clavulanate potassium therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Augmentin XR: Additional contraindications: Severe renal impairment (creatinine clearance &lt;30 mL/minute) and hemodialysis patients</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Suspected or confirmed mononucleosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134579\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, or history of sensitivity to multiple allergens.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diarrhea: Incidence of diarrhea is higher than with amoxicillin alone. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: Although rarely fatal, hepatic dysfunction (eg, cholestatic jaundice, hepatitis) has been reported. Patients at highest risk include those with serious underlying disease or concomitant medications. Hepatic toxicity is usually reversible. Monitor liver function tests at regular intervals in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Prolonged therapy: Monitor renal, hepatic, and hematopoietic function if therapy extends beyond approved duration times.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment and monitor liver function tests at regular intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infectious mononucleosis: A high percentage of patients with infectious mononucleosis have developed rash during therapy; ampicillin-class antibiotics not recommended in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy related issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Clavulanic acid content: Due to differing content of clavulanic acid, not all formulations are interchangeable; use of an inappropriate product for a specific dosage could result in either diarrhea (which may be severe) or subtherapeutic clavulanic acid concentrations leading to decreased clinical efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Phenylalanine: Some products contain phenylalanine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298742\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134584\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8676&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May enhance the potential for allergic or hypersensitivity reactions to Amoxicillin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134587\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134602\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Both amoxicillin and clavulanic acid cross the placenta. Maternal use of amoxicillin/clavulanate has generally not resulted in an increased risk of birth defects. A possible increased risk of necrotizing enterocolitis in neonates or bowel disorders in children exposed to amoxicillin/clavulanate in utero has been observed. In women with acute infections during pregnancy, amoxicillin/clavulanate may be given if an antibiotic is required and appropriate based on bacterial sensitivity; however, use is not recommended in the management of preterm premature rupture of membranes. Oral ampicillin-class antibiotics are poorly absorbed during labor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134603\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Amoxicillin is excreted in breast milk following administration amoxicillin/clavulanate (Weber 1984).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of amoxicillin following administration of amoxicillin/clavulanate is 0.02% to 0.07% when calculated using the highest average breast milk concentration located and compared to an infant therapeutic dose of 25 to 90 mg/kg/day. In general, breastfeeding is considered acceptable when the RID is &lt;10%; when an RID is &gt;25% breastfeeding should generally be avoided (Anderson 2016; Ito 2000). Using the highest average milk concentration (0.12 mcg/mL), the estimated daily infant dose via breast milk is 0.018 mg/kg/day. This milk concentration was obtained 4 to 6 hours following maternal administration of oral amoxicillin/clavulanate 250 mg/125 mg (Takase 1982).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Constipation, diarrhea, restlessness, and rash have been reported in breastfeeding infants exposed to amoxicillin and clavulanate; reversible elevations in AST and ALT have been noted in one infant (Benyamini 2005). The manufacturer warns of the potential for allergic sensitization in the infant. In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush and diarrhea (WHO 2002).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Although the manufacturer recommends that caution be exercised when administering amoxicillin and clavulanate to breastfeeding women, amoxicillin/clavulanate is considered compatible with breastfeeding when used in usual recommended doses (WHO 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134604\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May be taken with meals or on an empty stomach; take with meals to increase absorption and decrease GI upset; may mix with milk, formula, or juice. Extended release tablets should be taken with food. Some products may contain sodium. Some products contain phenylalanine; if you have phenylketonuria or PKU, avoid use. All dosage forms contain potassium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134589\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Assess patient at beginning and throughout therapy for infection; with prolonged therapy, monitor renal, hepatic, and hematologic function periodically; in patients with hepatic impairment, monitor liver function tests at regular intervals; monitor for signs of anaphylaxis during first dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134578\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Clavulanic acid binds and inhibits beta-lactamases that inactivate amoxicillin resulting in amoxicillin having an expanded spectrum of activity. Amoxicillin inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134597\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Amoxicillin pharmacokinetics are not affected by clavulanic acid.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Amoxicillin:</b> See individual Amoxicillin monograph. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Clavulanic acid:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Protein binding: ~25%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Half-life elimination: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Time to peak: 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Excretion: Urine (25% to 40% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134601\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Amoxicillin-Pot Clavulanate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200-28.5 mg (20): $56.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400-57 mg (20): $107.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Amoxicillin-Pot Clavulanate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200-28.5 mg/5 mL (100 mL): $36.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250-62.5 mg/5 mL (100 mL): $86.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400-57 mg/5 mL (100 mL): $68.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600-42.9 mg/5 mL (125 mL): $83.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Augmentin ES-600 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600-42.9 mg/5 mL (125 mL): $101.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Augmentin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125-31.25 mg/5 mL (100 mL): $667.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250-62.5 mg/5 mL (100 mL): $979.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Amoxicillin-Pot Clavulanate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000-62.5 mg (28): $187.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Augmentin XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000-62.5 mg (28): $225.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Amoxicillin-Pot Clavulanate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250-125 mg (30): $177.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500-125 mg (20): $75.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">875-125 mg (20): $101.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Augmentin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500-125 mg (20): $231.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">875-125 mg (20): $308.99</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869364\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acarbixin (MX);</li>\n      <li>Aclam (ID);</li>\n      <li>Addex (PH);</li>\n      <li>Alvoclav (SG);</li>\n      <li>Ambilan (CL);</li>\n      <li>Amiclav (ID);</li>\n      <li>AMK (HK, TH);</li>\n      <li>Amobay Cl (MX);</li>\n      <li>Amocla (KR);</li>\n      <li>Amoclan (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, TW, YE);</li>\n      <li>Amoclav (DE, IE);</li>\n      <li>Amoksiclav (CN, TH);</li>\n      <li>Amoksixlav (LV);</li>\n      <li>Amoxi Plus (PY);</li>\n      <li>Amoxic Comp (IS);</li>\n      <li>Amoxiclav (LU, MX);</li>\n      <li>Amoxiclav-BID (MX);</li>\n      <li>Amoxiclav-Teva (IL);</li>\n      <li>Amoxicle (KR);</li>\n      <li>Amoxxlin (KR);</li>\n      <li>Amoxyclav (IL);</li>\n      <li>An Qi (CN);</li>\n      <li>Augamox (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Augbidil (VN);</li>\n      <li>AugMaxcil (ZA);</li>\n      <li>Augmentan (DE);</li>\n      <li>Augmentin (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CN, CR, CY, CZ, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, IE, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KR, KW, LB, LK, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NZ, OM, PA, PE, PK, PL, PT, QA, RO, RU, SA, SC, SD, SI, SK, SL, SN, SR, SV, SY, TH, TN, TR, TT, TZ, UA, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Augmentin ES (IL);</li>\n      <li>Augmentin SR (TH);</li>\n      <li>Augmentine (ES);</li>\n      <li>Augmex (VN);</li>\n      <li>Auspilic (ID);</li>\n      <li>Bactiv (PH);</li>\n      <li>Bactoclav (PH);</li>\n      <li>Betaclav (LV);</li>\n      <li>Bioclavid (AE, BH, CY, DE, DK, EG, IQ, IR, JO, KW, LB, LY, OM, PH, QA, SA, SE, SY, YE);</li>\n      <li>Bioclavid Forte (PH);</li>\n      <li>Capsinat (ID);</li>\n      <li>Cavumox (MY, TH);</li>\n      <li>Clacillin Duo Dry Syrup (KR);</li>\n      <li>Clamentin (ZA);</li>\n      <li>Clamixin (ID);</li>\n      <li>Clamodia (VN);</li>\n      <li>Clamovid (HK, MY, SG);</li>\n      <li>Clamox (BD);</li>\n      <li>Clamoxin (MX);</li>\n      <li>Clamoxneo (KR);</li>\n      <li>Clamoxyl (AU);</li>\n      <li>Clamoxyl Duo 400 (AU);</li>\n      <li>Claudia (UA);</li>\n      <li>Clav-K (LK);</li>\n      <li>Clavam (LK, ZW);</li>\n      <li>Clavamel (IE);</li>\n      <li>Clavamox (CH, DE, ID, IN, JP);</li>\n      <li>Clavant (MX);</li>\n      <li>Clavar (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Claventin (IL);</li>\n      <li>Clavicin (MY);</li>\n      <li>Clavinex (CL, EC);</li>\n      <li>Clavipen (MX);</li>\n      <li>Clavmex (PH);</li>\n      <li>Clavodar (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Clavotec (LK);</li>\n      <li>Clavoxil (BR);</li>\n      <li>Clavucyd (MX);</li>\n      <li>Clavulin (BF, BJ, CI, CO, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MX, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Clavulin C (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Clavulox Duo (AR, PY);</li>\n      <li>Clavumox (DE, PE, ZA);</li>\n      <li>Clavuser (MX);</li>\n      <li>Coklav (TH);</li>\n      <li>Coyarin (ID);</li>\n      <li>Cramon Duo (KR);</li>\n      <li>Cramotin (KR);</li>\n      <li>Crasigen Duo (KR);</li>\n      <li>Curam (AE, AU, BH, CO, ET, HK, JO, KW, LB, LK, MY, PE, SA, SG, TH, TW, TZ, VN);</li>\n      <li>Danoclav (ID);</li>\n      <li>Darzitil Plus (AR);</li>\n      <li>Duonasa (ES);</li>\n      <li>E-Moxclav (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Enhancin (ET, LK, PH, ZW);</li>\n      <li>Fengkelin (CN);</li>\n      <li>Fleming (HK, TH, VN);</li>\n      <li>Fullicilina Plus (AR);</li>\n      <li>GA-Amclav (AU);</li>\n      <li>Genclav (PH);</li>\n      <li>Germentin (IE);</li>\n      <li>Gimaclav (MX);</li>\n      <li>Haikela (CN);</li>\n      <li>Hibiotic (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ind Clav (TH);</li>\n      <li>Julmentin (TH);</li>\n      <li>Klamonex (KR);</li>\n      <li>Klamos Forte (ET);</li>\n      <li>Klavic (PH);</li>\n      <li>Kmoxilin (KR);</li>\n      <li>Koact (SG);</li>\n      <li>Koakt (UA);</li>\n      <li>Lansiclav (ID);</li>\n      <li>Luvmox (PH);</li>\n      <li>Moxiclav (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IE, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SG, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Moxicle (TH);</li>\n      <li>Moxilin CV (BD);</li>\n      <li>Moxlin (MX);</li>\n      <li>Myclav (ET, LK, ZW);</li>\n      <li>Natravox (PH);</li>\n      <li>Neoclav (TZ);</li>\n      <li>Novamox (BR);</li>\n      <li>Nufaclav (ID);</li>\n      <li>Okaclav 457 DT (TH);</li>\n      <li>Penhance (PH);</li>\n      <li>pms-Claminat (VN);</li>\n      <li>Quali-Mentin (HK);</li>\n      <li>Ranclav (TH, ZA);</li>\n      <li>Riclasip (MX);</li>\n      <li>Servamox (MX);</li>\n      <li>Sheng Ai (CN);</li>\n      <li>Sinufin (MX);</li>\n      <li>Spektramox (SE);</li>\n      <li>Sullivan (PH);</li>\n      <li>Synclav (TZ);</li>\n      <li>Synermox (NZ);</li>\n      <li>Tedavi (VN);</li>\n      <li>Tyclav (BD);</li>\n      <li>Vestaclav (MY);</li>\n      <li>Viaclav (ID);</li>\n      <li>Viamox (PH);</li>\n      <li>Vulamox (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds; <i>Red Book: 2012 </i><i>Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media, &quot;Diagnosis and Management of Acute Otitis Media,&quot; <i>Pediatrics</i>, 2004, 113(5):1451-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/15121972/pubmed\" target=\"_blank\" id=\"15121972\">15121972</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Practice bulletin no. 160: premature rupture of membranes. <i>Obstet Gynecol</i>. 2016;127(1):e39-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/26695586 /pubmed\" target=\"_blank\" id=\"26695586 \">26695586 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Thoracic Society, &ldquo;Guidelines for the Initial Management of Adults With Community-Acquired Pneumonia: Diagnosis, Assessment of Severity, and Initial Antimicrobial Therapy,&rdquo; <i>Am Rev Respir Dis</i>, 1993, 148(5):1418-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/8239186/pubmed\" target=\"_blank\" id=\"8239186\">8239186</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ancill RJ, Ballard JH, and Capewell MA, &ldquo;Urinary Tract Infections in Geriatric Inpatients: A Comparative Study of Amoxicillin-Clavulanic Acid and Co-trimoxazole,&rdquo; <i>Curr Ther Res Clin Exp</i>, 1987, 41(4):444-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, eds. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benyamini L, Merlob P, Stahl B, et al, &quot;The Safety of Amoxicillin/Clavulanic Acid and Cefuroxime During Lactation,&quot; <i>Ther Drug Monit</i>, 2005, 27(4):499-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/16044108/pubmed\" target=\"_blank\" id=\"16044108\">16044108</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS. Management of community-acquired pediatric pneumonia in an era of increasing antibiotic resistance and conjugate vaccines. <i>Pediatr Infect Dis J</i>. 2002;21(6):592-598.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/12182396/pubmed\" target=\"_blank\" id=\"12182396\">12182396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. <i>Clin Infect Dis</i>. 2012;54(8):e72-e112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow MS, Quintiliani R, and Nightingale CH, &quot;<i>In Vivo</i> Inactivation of Tobramycin by Ticarcillin. A Case Report,&quot; <i>JAMA</i>, 1982, 247(5):658-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/6798229/pubmed\" target=\"_blank\" id=\"6798229\">6798229</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clavulin (amoxicillin and clavulanic acid) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; Fbruary 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daly JS, Dodge RA, Glew RH, et al, &quot;Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages,&quot; <i>J Perinatol</i>, 1997, 17(1):42-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/9069064/pubmed\" target=\"_blank\" id=\"9069064\">9069064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo; <i>N Engl J Med</i>, 1988, 318(7):419-26 and 318(8):490-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/3277054/pubmed\" target=\"_blank\" id=\"3277054\">3277054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell JA, Korth-Bradley J, Milisci M, et al, &ldquo;Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment,&rdquo; <i>J Clin Pharmacol</i>, 2001, 41:979-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/11549103/pubmed\" target=\"_blank\" id=\"11549103\">11549103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farchione LA, &ldquo;Inactivation of Aminoglycosides by Penicillins,&rdquo; <i>J Antimicrob Chemother</i>, 1982, 8(Suppl A):27-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/7263563/pubmed\" target=\"_blank\" id=\"7263563\">7263563</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2013;31(6):794-810.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/23319691/pubmed\" target=\"_blank\" id=\"23319691\">23319691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):e56-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/21258094/pubmed\" target=\"_blank\" id=\"21258094\">21258094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrilepatients with neutropenia during cancer chemotherapy. <i>N Engl J Med</i>. 1999;341(5):305-311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/10423464/pubmed\" target=\"_blank\" id=\"10423464\">10423464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuchs PC, Stickel S, Anderson PH, et al, &ldquo;<i>In Vitro</i> Inactivation of Aminoglycosides by Sulbactam, Other Beta-Lactams, and Sulbactam-Beta-Lactam Combinations,&rdquo; <i>Antimicrob Agents Chemother</i>, 1991, 35(1):182-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/2014975/pubmed\" target=\"_blank\" id=\"2014975\">2014975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gan VN, Kusmiesz H, Shelton S, et al, &ldquo;Comparative Evaluation of Loracarbef and Amoxicillin-Clavulanate for Acute Otitis Media,&rdquo; <i>Antimicrob Agents Chemother</i>, 1991, 35(5):967-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/1854178/pubmed\" target=\"_blank\" id=\"1854178\">1854178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-e120.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/21292654/pubmed\" target=\"_blank\" id=\"21292654\">21292654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halstenson CE, Wong MO, Herman CS, et al, &ldquo;Effect of Concomitant Administration of Piperacillin on the Dispositions on Isepamicin and Gentamicin in Patients With End-Stage Renal Disease,&rdquo; <i>Antimicrob Agents Chemother</i>, 1992, 36(9):1832-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/1416875/pubmed\" target=\"_blank\" id=\"1416875\">1416875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hitt CM, Patel KB, Nicolau DP, et al, &ldquo;Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily,&rdquo; <i>Am J Health Syst Pharm</i>, 1997, 54(23):2704-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/9408514/pubmed\" target=\"_blank\" id=\"9408514\">9408514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoberman A, Paradise JL, Burch DJ, et al, &ldquo;Equivalent Efficiency and Reduced Occurrence of Diarrhea From a New Formulation of Amoxicillin/Clavulanate Potassium (Augmentin&reg;) for Treatment of Acute Otitis Media in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1997, 16(5):463-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/9154538/pubmed\" target=\"_blank\" id=\"9154538\">9154538</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Konishi H, Goto M, Nakamoto Y, et al, &quot;Tobramycin Inactivation by Carbenicillin, Ticarcillin, and Piperacillin,&quot; <i>Antimicrob Agents Chemother</i>, 1983, 23(5):653-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/6223576/pubmed\" target=\"_blank\" id=\"6223576\">6223576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lau A, Lee M, Flascha S, et al, &quot;Effect of Piperacillin on Tobramycin Pharmacokinetics in Patients With Normal Renal Function,&quot; <i>Antimicrob Agents Chemother</i>, 1983, 24(4):533-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/6651279/pubmed\" target=\"_blank\" id=\"6651279\">6651279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media [published correction appears in <i>Pediatrics</i>. 2014;133(2):346]. <i>Pediatrics</i>. 2013;131(3):e964-e999.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/23439909/pubmed\" target=\"_blank\" id=\"23439909\">23439909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsitz R, Garges S, Aurigemma R, et al. Workshop on treatment of and postexposure prophylaxis for <i>Burkholderia pseudomallei</i> and <i>B. mallei Infection</i>, 2010. <i>Emerg Infect Dis</i>. 2012;18(12):e2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/23171644/pubmed\" target=\"_blank\" id=\"23171644\">23171644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al, &quot;2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Llor C, Moragas A, Hernandez S, Bayona C, Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. <i>Am J Respir Crit Care Med</i> 2012;186(8):716-723.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/22923662/pubmed\" target=\"_blank\" id=\"22923662\">22923662</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the managementof community-acquired pneumonia in adults. <i>Clin Infect Dis</i>. 2007;44(suppl 2):S27-S72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/17278083/pubmed\" target=\"_blank\" id=\"17278083\">17278083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pherwani N, Ghayad JM, Holle LM, Karpiuk EL. Outpatient management of febrile neutropenia associated with cancer chemotherapy: risk stratification and treatment review. <i>Am J Health Syst Pharm</i>. 2015;72(8):619-613.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/25825185/pubmed\" target=\"_blank\" id=\"25825185\">25825185</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reed MD, &ldquo;Clinical Pharmacokinetics of Amoxicillin and Clavulanate,&rdquo; <i>Pediatr Infect Dis J</i>, 1996, 15(10):949-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/8895939/pubmed\" target=\"_blank\" id=\"8895939\">8895939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(2 suppl):S1-S39. doi: 10.1177/0194599815572097.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/25832968/pubmed\" target=\"_blank\" id=\"25832968\">25832968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Russoe ME and Atkins-Thor E, &quot;Gentamicin and Ticarcillin in Subjects With End-Stage Renal Disease. Comparison of Two Assay Methods and Evaluation of Inactivation Rate,&quot; <i>Clin Nephrol</i>, 1981, 15(4):175-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/7237864/pubmed\" target=\"_blank\" id=\"7237864\">7237864</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman ST, Bisno AL, Clegg HW, et al, &ldquo;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2012, 55(10):e86-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/22965026/pubmed\" target=\"_blank\" id=\"22965026\">22965026</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi: 10.1093/cid/ciu444.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/24973422/pubmed\" target=\"_blank\" id=\"24973422\">24973422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. <i>Pediatrics</i>. 2011;128(3):595-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/21873693/pubmed\" target=\"_blank\" id=\"21873693\">21873693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Swanson-Biearman B, Dean DS, Lopez G, et al, &quot;The Effects of Penicillin and Cephalosporin Ingestions in Children Less Than Six Years of Age,&quot; <i>Vet Hum Toxicol</i>, 1988, 30(1):66-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/3354190/pubmed\" target=\"_blank\" id=\"3354190\">3354190</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Takase Z, Shirafuji H, Uchida M. Clinical and Laboratory Studies on BRL25000 (Clavulanic acid-amoxicillin) in the field of obstetrics and gynecology. <i>Japanese Journal of Chemotherapy </i>1982;30(Suppl 2):579-586.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thoene DE and Johnson CE, &ldquo;Pharmacotherapy of Otitis Media,&rdquo; <i>Pharmacotherapy</i>, 1991, 11(3):212-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/1862012/pubmed\" target=\"_blank\" id=\"1862012\">1862012</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thompson MIB, Russo ME, Saxon BJ, et al, &quot;Gentamicin Inactivation by Piperacillin or Carbenicillin in Patients With End-Stage Renal Disease,&quot; <i>Antimicrob Agents Chemother</i>, 1982, 21(2):268-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/6462107/pubmed\" target=\"_blank\" id=\"6462107\">6462107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Todd PA and Benfield P, &ldquo;Amoxicillin/Clavulanic Acid. An Update of Its Antibacterial Activity, Pharmacokinetic Properties, and Therapeutic Use,&rdquo; <i>Drugs</i>, 1990, 39(2):264-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/2184003/pubmed\" target=\"_blank\" id=\"2184003\">2184003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tu YH, Stiles ML, Allen LV Jr, et al, &ldquo;Stability of Amoxicillin Trihydrate-Potassium Clavulanate in Original Containers and Unit Dose Oral Syringes,&rdquo; <i>Am J Hosp Pharm</i>, 1988, 45(5):1092-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/3400652 /pubmed\" target=\"_blank\" id=\"3400652 \">3400652 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Viollier AF, Standiford HC, Drusano GL, et al, &quot;Comparative Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin, Ticarcillin and Piperacillin, With and Without Gentamicin,&quot; <i>J Antimicrob Chemother</i>, 1985, 15(5):597-606.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/4008387/pubmed\" target=\"_blank\" id=\"4008387\">4008387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wald ER, Applegate KE, Bordley C, et al; American Academy of Pediatrics. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. <i>Pediatrics</i>. 2013;132(1):e262-e280.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/23796742/pubmed\" target=\"_blank\" id=\"23796742\">23796742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walterspiel JN, Feldman S, Van R, et al, &quot;Comparative Inactivation of Isepamicin, Amikacin, and Gentamicin by Nine Beta-Lactams and Two Beta-Lactamase Inhibitors, Cilastatin and Heparin,&quot; <i>Antimicrob Agents Chemother</i>, 1991, 35(9):1875-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/1952861/pubmed\" target=\"_blank\" id=\"1952861\">1952861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber DJ, Tolkoff-Rubin NE, and Rubin RH, &quot;Amoxicillin and Potassium Clavulanate: An Antibiotic Combination. Mechanism of Action, Pharmacokinetics, Antimicrobial Spectrum, Clinical Efficacy and Adverse Effects,&quot; <i>Pharmacotherapy</i>, 1984, 4(3):122-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/6739312/pubmed\" target=\"_blank\" id=\"6739312\">6739312</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/23215911</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wright AJ, &ldquo;The Penicillins,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(3):290-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/10090000/pubmed\" target=\"_blank\" id=\"10090000\">10090000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL and Bergman SA, &ldquo;Antibiotics and Their Use in the Treatment of Orofacial Infections, Part I and Part II,&rdquo; <i>Gen Dent</i>, 1994, 42(5):398-402, 498-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amoxicillin-and-clavulanate-drug-information/abstract-text/7489869/pubmed\" target=\"_blank\" id=\"7489869\">7489869</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8676 Version 168.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F134614\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F134615\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F134635\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F134618\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F134628\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F134619\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F134620\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15673178\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F134591\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F134575\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F21964564\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F134595\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F134594\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475042\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F134644\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F134582\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F134598\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F134579\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298742\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F134584\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F134587\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F134602\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F134603\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F134604\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F134589\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F134578\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F134597\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F134601\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F2869364\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8676|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amoxicillin-and-clavulanate-patient-drug-information\" class=\"drug drug_patient\">Amoxicillin and clavulanate: Patient drug information</a></li><li><a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">Amoxicillin and clavulanate: Pediatric drug information</a></li></ul></div></div>","javascript":null}